Article citationsMore>>
Hashinaga, M., Okimoto, T., Kodama, M., Mizukami, K., Ogawa, R., Okamoto, K., Shuto, M., Fukuda, K., Sonoda, H., Fukuda, M., Honda, S., Yamaoka, Y. and Murakami, K. (2016) わが国における薬剤耐性Helicobacter pyloriの現状—2013-2014年度耐性菌サーベイランスの集計報告. [Current Status of Drug Resistance Helicobacter Pylori in Japan—Total Report of Resistant Bacterial Surveillance for 2013 to 2014.] Japanese Journal of Helicobacter Research, 45-49. (In Japanese)
has been cited by the following article:
-
TITLE:
Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for Helicobacter pylori
AUTHORS:
Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, Sho Suzuki
KEYWORDS:
Vonoprazan, Eradication, Helicobacter pylori, Propensity Score Matching, Gastric Mucosal Atrophy
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.7 No.9,
September
28,
2017
ABSTRACT: Aim: To investigate the factors related to the effect of eradication therapy with vonoprazan for Helicobacter pylori (H. pylori). Methods: We retrospectively reviewed medical records of H. pylori-positive patients who received first-line (40 mg vonoprazan/60 mg lansoprazole or 20 mg rabeprazole, 1500 mg amoxicillin, 400 mg clarithromycin, all 2/day for 7 days) (n = 4118). H. pylori eradication was assessed by the 13C-urea breath test with success defined as a result of H. pylori eradication therapy using vonoprazan was more effective than standard triple therapy with proton pump inhibitor. Gastric mucosal atrophy was associated with treatment success.